Lenard A. Adler has disclosed the following relevant financial relationships: research grants from Takeda and Otsuka Pharmaceuticals; consultant for Bracket/Signant, Supernus Pharmaceuticals ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to acquire Sage Therapeutics, Inc. (SAGE) for up to $795 ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. <li /> S ...

Supernus Pharmaceuticals Inc. stock grades by Barron's. View SUPN fundamental and sentiment analysis powered by MarketGrader.

Supernus Pharmaceuticals Inc. company and executive profile by Barron's. View the latest SUPN company infomation and executive bios.

The OnPage System The new integration streamlines high-priority ticket escalation and ensures real-time, actionable alerts for faster resolution and minimized downtime. Implementing the OnPage ...